PH II study of adjuvant tx with cisplatin-based chemotherapy plus concomitant atezolizumab in patients with stage I (tumors > 4cm) IIA IIB and select IIIA [T3N1 T4N0-1] resected NSCLC and the clearance of (ctDNA)

Brief description of study

The purpose of the study is to determine and estimate the percentage of patients with undetectable circulating tumor DNA (ctDNA) after 4 cycles of adjuvant chemotherapy + Atezolizumab plus up to 13 additional cycles of Atezolizumab in patients with stage I (tumors = 4cm), IIA, IIB, and select IIIA [T3N1-2, T4N0-2] NSCLC who have detectable ctDNA after surgery, but prior to adjuvant therapy.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.